[Form 4] Gyre Therapeutics, Inc. Insider Trading Activity
Gyre Therapeutics director Dan Weng was granted a stock option on 08/18/2025 to buy 52,000 shares of common stock at an exercise price of $7.85 per share. The option has a 10-year term expiring 08/18/2035 and vests in 36 equal monthly installments through 08/18/2028, subject to continued service. Following the reported transaction the Reporting Person beneficially owns 52,000 option shares on a direct basis. The Form 4 was filed as a single reporting person and signed by an attorney-in-fact on 08/26/2025.
Il direttore di Gyre Therapeutics, Dan Weng, ha ricevuto in data 18/08/2025 un'opzione su azioni per acquistare 52.000 azioni ordinarie al prezzo di esercizio di $7,85 per azione. L'opzione ha una durata di 10 anni con scadenza il 18/08/2035 e matura in 36 rate mensili uguali fino al 18/08/2028, subordinatamente alla prosecuzione del servizio. A seguito dell'operazione segnalata, la Persona Segnalante detiene beneficiariamente 52.000 azioni opzionate su base diretta. Il Modulo 4 猫 stato depositato come persona segnalante unica e firmato da un procuratore il 26/08/2025.
El director de Gyre Therapeutics, Dan Weng, recibi贸 el 18/08/2025 una opci贸n sobre acciones para comprar 52.000 acciones ordinarias a un precio de ejercicio de $7,85 por acci贸n. La opci贸n tiene un plazo de 10 a帽os con vencimiento el 18/08/2035 y se consolida en 36 cuotas mensuales iguales hasta el 18/08/2028, sujeto a la continuidad del servicio. Tras la operaci贸n comunicada, la Persona Informante posee beneficiariamente 52.000 acciones opci贸nadas en forma directa. El Formulario 4 se present贸 como persona informante 煤nica y fue firmado por un apoderado el 26/08/2025.
Gyre Therapeutics鞚� 鞚挫偓 Dan Weng鞚� 2025-08-18鞐� 氤错喌欤� 52,000欤茧ゼ 欤茧嫻 頄夓偓 臧�瓴� $7.85鞐� 毵れ垬頃� 靾� 鞛堧姅 鞀ろ啞鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 鞓奠厴鞚� 鞙犿毃旮瓣皠鞚� 10雲勳溂搿� 2035-08-18鞐� 毵岆霅橂┌, 瓿勳啀 攴茧毳� 鞝勳牅搿� 2028-08-18旯岇 毵れ洈 霃欖澕頃� 36須� 攵勴暊搿� 氩犾姢韺呺惄雼堧嫟. 氤搓碃霅� 瓯半灅 鞚错泟 氤搓碃鞚胳潃 歆侅为 氚╈嫕鞙茧 52,000欤检潣 鞓奠厴 欤检嫕鞚� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Form 4電� 雼澕 氤搓碃鞚胳溂搿� 鞝滌稖霅橃棃瓿� 2025-08-26鞐� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Le directeur de Gyre Therapeutics, Dan Weng, s鈥檈st vu accorder le 18/08/2025 une option d鈥檃chat de 52 000 actions ordinaires au prix d鈥檈xercice de 7,85 $ par action. L鈥檕ption a une dur茅e de 10 ans et expire le 18/08/2035 ; elle acquiert ses droits par 36 versements mensuels 茅gaux jusqu鈥檃u 18/08/2028, sous r茅serve de la poursuite du service. Suite 脿 la transaction d茅clar茅e, la personne d茅clarante d茅tient 脿 titre b茅n茅ficiaire 52 000 actions optionnelles de mani猫re directe. Le formulaire 4 a 茅t茅 d茅pos茅 en tant que personne d茅clarante unique et sign茅 par un mandataire le 26/08/2025.
Gyre Therapeutics-Direktor Dan Weng wurde am 18.08.2025 eine Aktienoption gew盲hrt, 52.000 Stammaktien zu einem Aus眉bungspreis von $7,85 pro Aktie zu kaufen. Die Option hat eine Laufzeit von 10 Jahren und l盲uft am 18.08.2035 ab; sie vestet in 36 gleichen monatlichen Raten bis zum 18.08.2028, vorbehaltlich fortgesetzter T盲tigkeit. Nach der gemeldeten Transaktion besitzt die meldepflichtige Person anteilig 52.000 Optionsaktien auf direktem Wege. Das Formular 4 wurde als einzelne meldende Person eingereicht und am 26.08.2025 von einem Bevollm盲chtigten unterzeichnet.
- None.
- None.
Insights
TL;DR: Routine equity-based director compensation; grants align incentives without an immediate cash impact.
The 52,000-option grant at $7.85 is a standard long-term incentive for a director, with a 10-year term and a 3-year monthly vesting schedule. This structure ties the directors compensation to future share performance and preserves cash in the near term. The grant increases potential dilution if exercised but does not represent an immediate transfer of shares or cash. No other financial metrics or performance conditions are disclosed in the filing.
TL;DR: Governance-wise this appears routine; vesting requires continued service, aligning director retention with shareholder interests.
The vesting in 36 equal monthly installments through August 2028 indicates a retention focus rather than performance-based pay. The direct ownership reporting clarifies the grant is held by the reporting person. The Form 4 is properly filed and signed by an attorney-in-fact, showing procedural compliance. The filing contains no disclosure of board approvals or compensation committee details.
Il direttore di Gyre Therapeutics, Dan Weng, ha ricevuto in data 18/08/2025 un'opzione su azioni per acquistare 52.000 azioni ordinarie al prezzo di esercizio di $7,85 per azione. L'opzione ha una durata di 10 anni con scadenza il 18/08/2035 e matura in 36 rate mensili uguali fino al 18/08/2028, subordinatamente alla prosecuzione del servizio. A seguito dell'operazione segnalata, la Persona Segnalante detiene beneficiariamente 52.000 azioni opzionate su base diretta. Il Modulo 4 猫 stato depositato come persona segnalante unica e firmato da un procuratore il 26/08/2025.
El director de Gyre Therapeutics, Dan Weng, recibi贸 el 18/08/2025 una opci贸n sobre acciones para comprar 52.000 acciones ordinarias a un precio de ejercicio de $7,85 por acci贸n. La opci贸n tiene un plazo de 10 a帽os con vencimiento el 18/08/2035 y se consolida en 36 cuotas mensuales iguales hasta el 18/08/2028, sujeto a la continuidad del servicio. Tras la operaci贸n comunicada, la Persona Informante posee beneficiariamente 52.000 acciones opci贸nadas en forma directa. El Formulario 4 se present贸 como persona informante 煤nica y fue firmado por un apoderado el 26/08/2025.
Gyre Therapeutics鞚� 鞚挫偓 Dan Weng鞚� 2025-08-18鞐� 氤错喌欤� 52,000欤茧ゼ 欤茧嫻 頄夓偓 臧�瓴� $7.85鞐� 毵れ垬頃� 靾� 鞛堧姅 鞀ろ啞鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 鞓奠厴鞚� 鞙犿毃旮瓣皠鞚� 10雲勳溂搿� 2035-08-18鞐� 毵岆霅橂┌, 瓿勳啀 攴茧毳� 鞝勳牅搿� 2028-08-18旯岇 毵れ洈 霃欖澕頃� 36須� 攵勴暊搿� 氩犾姢韺呺惄雼堧嫟. 氤搓碃霅� 瓯半灅 鞚错泟 氤搓碃鞚胳潃 歆侅为 氚╈嫕鞙茧 52,000欤检潣 鞓奠厴 欤检嫕鞚� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Form 4電� 雼澕 氤搓碃鞚胳溂搿� 鞝滌稖霅橃棃瓿� 2025-08-26鞐� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Le directeur de Gyre Therapeutics, Dan Weng, s鈥檈st vu accorder le 18/08/2025 une option d鈥檃chat de 52 000 actions ordinaires au prix d鈥檈xercice de 7,85 $ par action. L鈥檕ption a une dur茅e de 10 ans et expire le 18/08/2035 ; elle acquiert ses droits par 36 versements mensuels 茅gaux jusqu鈥檃u 18/08/2028, sous r茅serve de la poursuite du service. Suite 脿 la transaction d茅clar茅e, la personne d茅clarante d茅tient 脿 titre b茅n茅ficiaire 52 000 actions optionnelles de mani猫re directe. Le formulaire 4 a 茅t茅 d茅pos茅 en tant que personne d茅clarante unique et sign茅 par un mandataire le 26/08/2025.
Gyre Therapeutics-Direktor Dan Weng wurde am 18.08.2025 eine Aktienoption gew盲hrt, 52.000 Stammaktien zu einem Aus眉bungspreis von $7,85 pro Aktie zu kaufen. Die Option hat eine Laufzeit von 10 Jahren und l盲uft am 18.08.2035 ab; sie vestet in 36 gleichen monatlichen Raten bis zum 18.08.2028, vorbehaltlich fortgesetzter T盲tigkeit. Nach der gemeldeten Transaktion besitzt die meldepflichtige Person anteilig 52.000 Optionsaktien auf direktem Wege. Das Formular 4 wurde als einzelne meldende Person eingereicht und am 26.08.2025 von einem Bevollm盲chtigten unterzeichnet.
FAQ
What option grant did Gyre Therapeutics (GYRE) report for director Dan Weng?
When do the options vest and when do they expire?
How many shares does the reporting person beneficially own after the transaction?
Who filed and signed the Form 4 for this transaction?
Is there any cash paid on grant according to the Form 4?
